Cargando…
Focal Adhesion Kinase Provides a Collateral Vulnerability That Can Be Leveraged to Improve mTORC1 Inhibitor Efficacy
SIMPLE SUMMARY: While the PI3K/AKT/mTORC1 pathway is highly active in breast cancer, mTORC1-targeting drugs are not effective in all breast cancer subtypes. To identify potential resistance mechanisms, we utilized a mouse model of breast cancer that continues to grow in the presence of the mTORC1 in...
Autores principales: | Cuellar-Vite, Leslie, Weber-Bonk, Kristen L., Abdul-Karim, Fadi W., Booth, Christine N., Keri, Ruth A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9323520/ https://www.ncbi.nlm.nih.gov/pubmed/35884439 http://dx.doi.org/10.3390/cancers14143374 |
Ejemplares similares
-
mTORC1 activity is supported by spatial association with focal adhesions
por: Rabanal-Ruiz, Yoana, et al.
Publicado: (2021) -
Both mTORC1 and mTORC2 are involved in the regulation of cell adhesion
por: Chen, Long, et al.
Publicado: (2015) -
LPS Induces mTORC1 and mTORC2 Activation During Monocyte Adhesion
por: Ribeiro, Marcelle C., et al.
Publicado: (2018) -
mTORC1 and mTORC2 in cancer and the tumor microenvironment
por: Kim, Laura C., et al.
Publicado: (2016) -
Targeted therapy for mTORC1-driven tumours through HDAC inhibition by exploiting innate vulnerability of mTORC1 hyper-activation
por: Yang, Fuchun, et al.
Publicado: (2020)